Latest News and Press Releases
Want to stay updated on the latest news?
-
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Visual Disturbances
-
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
-
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
-
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
-
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
-
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
-
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
-
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
-
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)